Skip to main content
Retour
INDV logo

Indivior Pharmaceuticals Inc

Qualité des données : 100%
INDV
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
29,39 €
▲ 0,09 € (0,31%)
Cap. Boursière : 3,67B
Fourchette du Jour
29,22 € 30,69 €
Fourchette 52 Semaines
8,64 € 38,00 €
Volume
4 058 471
Moyenne 50J / 200J
33,28 € / 26,76 €
Clôture Précédente
29,30 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 17,5 0,4
P/B 2,9
ROE % 3,7
Net Margin % 17,0 3,9
Rev Growth 5Y % 11,9 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
43,75 € +48.9%
Low: 36,00 € High: 50,00 €
P/E Prévisionnel
9,4
BPA Prévisionnel
3,12 €
Croissance BPA (est.)
+0,0%
CA Est.
1,2 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 4,15 €
4,01 € – 4,32 €
1,4 B 1
FY2029 3,84 €
3,71 € – 4,00 €
1,4 B 1
FY2028 3,81 €
3,68 € – 3,97 €
1,3 B 1

Points Clés

Revenue grew 11,87% annually over 5 years — strong growth
Earnings grew 10400,00% over the past year
Net margin of 16,95% shows strong profitability
Negative free cash flow of -93,00M
PEG of 0,00 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,58%

Croissance

Revenue Growth (5Y)
11,87%
Revenue (1Y)4,29%
Earnings (1Y)10400,00%
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC77,67%
Net Margin16,95%
Op. Margin21,15%

Sécurité

Debt / Equity
N/A
Current Ratio0,71
Interest Coverage5,82

Valorisation

P/E Ratio
17,46
P/B RatioN/A
EV/EBITDA14,59
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4,29% Revenue Growth (3Y) 6,47%
Earnings Growth (1Y) 10400,00% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 11,87% Earnings Growth (5Y) 0,60%
Profitability
Revenue (TTM) 1,24B Net Income (TTM) 210,00M
ROE N/A ROA 17,44%
Gross Margin 80,23% Operating Margin 21,15%
Net Margin 16,95% Free Cash Flow (TTM) -93,00M
ROIC 77,67% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,71
Interest Coverage 5,82 Dividend Yield 0,00%
Valuation
P/E Ratio 17,46 P/B Ratio N/A
P/S Ratio 2,96 PEG Ratio 0,00
EV/EBITDA 14,59 Dividend Yield 0,00%
Market Cap 3,67B Enterprise Value 3,82B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,24B 1,19B 1,09B 901,00M 791,00M
Net Income 210,00M 2,00M -129,00M -44,00M 205,00M
EPS (Diluted) 1,64 0,02 0,01 -0,37 1,31
Gross Profit 994,00M 957,00M 919,00M 750,00M 664,00M
Operating Income 262,00M 32,00M -156,00M -81,00M 213,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,20B 1,32B 1,77B 1,78B 1,83B
Total Liabilities 1,30B 1,67B 1,96B 1,73B 1,63B
Shareholders' Equity -98,00M -348,00M -191,00M 51,28M 203,00M
Total Debt 351,00M 375,00M 283,00M 277,00M 286,00M
Cash & Equivalents 195,00M 319,00M 316,00M 778,18M 1,10B
Current Assets 652,00M 839,00M 1,27B 1,27B 1,44B
Current Liabilities 914,00M 939,00M 1,29B 1,02B 804,00M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#209 of 326
44

Activité Récente

Entré Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026